Market Movers: G1 (GTHX) Gains 7.29% to Close at $5.30 June 23

Equities Staff  |

G1 Therapeutics Inc (NASDAQ:GTHX) stock was among today's market movers, finishing trading up 7.29% to $5.30 on June 23.

1,045,049 shares exchanged hands while the 30-day daily average of 1,457,191 shares.

The company's stock has risen 51.62% so far in 2022.

G1 shares have traded in a range between $3.84 and $24.12 over the past twelve months.

The company anticipates its next earnings on 2022-08-03.

For technical charts, analysis, and more on G1 visit the company profile.

About G1 Therapeutics Inc

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.

To get more information on G1 Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: G1 Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content